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Background: Increased reactive oxygen species (ROS) production is involved in the process of adverse cardiac re-
modeling and development of heart failure after myocardial infarction (MI). NADPH oxidase-2 (Nox2) is a major
ROS sourcewithin the heart and its activity increases afterMI. Furthermore, genetic deletion of Nox2 is protective
against post-MI cardiac remodeling. Nox2 levels may increase both in cardiomyocytes and endothelial cells and
recent studies indicate cell-speciﬁc effects of Nox2, but it is not known which of these cell types is important in
post-MI remodeling.
Methods and results:Wehave generated transgenicmousemodels inwhich Nox2 expression is targeted either to
cardiomyocytes (cardio-Nox2TG) or endothelial cells (endo-Nox2TG). We here studied the response of cardio-
Nox2TGmice, endo-Nox2TGmice andmatchedwild-type littermates (WT) toMI induced by permanent left cor-
onary artery ligation up to 4weeks. Initial infarct size assessed bymagnetic resonance imaging (MRI) and cardiac
dysfunctionwere similar among groups. Cardiomyocyte hypertrophy and interstitial ﬁbrosis were augmented in
cardio-Nox2TG compared to WT after MI and post-MI survival tended to be worse whereas endo-Nox2TG mice
showed no signiﬁcant difference compared to WT.
Conclusions: These results indicate that cardiomyocyte rather than endothelial cell Nox2 may have the more im-
portant role in post-MI remodeling.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Myocardial infarction (MI) is a major cause of heart failure, second-
ary to progressive adverse left ventricular (LV) remodeling and impair-
ment of contractile function. Adverse cardiac remodeling post-MI is
characterized by progressive LV chamber dilatation, interstitial ﬁbrosis,
cardiomyocyte hypertrophy in non-infarcted tissue, and decline in con-
tractile performance. An increased production of reactive oxygen spe-
cies (ROS) and oxidative stress have long been recognized to be
involved in the process of post-MI remodeling and heart failure [1–3].
ROS contribute to adverse LV remodeling throughmultiplemechanisms
includingdetrimental effects on cellular components, impaired energet-
ics, alterations in various redox-sensitive signaling pathways and
changes in cardiomyocyte viability.
NADPH oxidases (Noxs) are major ROS sources in the heart, with
Nox2 (also known as gp91phox) and Nox4 being the two main isoforms
that are expressed [4]. Both isoforms require heterodimerization with a
p22phox subunit but Nox2 additionally requires association with several
cytosolic subunits (p47phox, p67phox, p40phox and Rac1) to manifest full
activity [5]. Therefore, Nox2 is acutely activated by agonists that pro-
mote the association of cytosolic subunits with the transmembrane
Nox2-p22phox complex [6] whereas Nox4 activity depends mainly on
its abundance [7]. Numerous studies indicate that the activation of
Nox2may contribute to the development of cardiac hypertrophy, inter-
stitial ﬁbrosis and contractile dysfunction in diverse disease situations
[8]. Previous studies using gene-modiﬁed mice with a global deﬁciency
of Nox2 found that Nox2 contributes to adverse LV remodeling and con-
tractile dysfunction after experimental MI [9,10]. Knockout (KO) mice
lacking either Nox2 or p47phoxwere protected against LVdilatation, car-
diomyocyte hypertrophy, apoptosis and interstitialﬁbrosis in theweeks
afterMI as comparedwithwild-type (WT) controls [9,10]. Thiswas sup-
ported by the ﬁnding that Nox2 is upregulated in the infarcted myocar-
dium after acute MI in patients [11] as well as in experimental models
[9,10,12–14].
Nox2 in the heart is expressed both in cardiomyocytes and endothe-
lial cells and its activation in these cell types may have different effects
[8]. Recently, we have generated transgenic mouse models in which
Nox2 is speciﬁcally overexpressed either in endothelial cells (endo-
Nox2TG) [15] or cardiomyocytes (cardio-Nox2TG) [16], in order to
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study the cell-speciﬁc effects of the oxidase.We found that in amodel of
chronic angiotensin II (AngII) infusion, endo-Nox2TG mice developed
greater myocardial ﬁbrosis and diastolic LV dysfunction thanWT litter-
mates [17]. In cardio-Nox2TG mice on the other hand, chronic AngII in-
fusion enhanced contractile function through an increase in
sarcoplasmic reticulum (SR) calcium uptake, while more prolonged
stress induced by chronic aortic constriction tended to worsen cardiac
dysfunction as compared to WT littermates [16]. Therefore, cardiac
Nox2 may affect the response to pathological insults in a cell-speciﬁc
and stress-speciﬁc manner. The aim of the current study was to com-
pare the effects of cardiomyocyte versus endothelial Nox2 on the cardi-
ac response to experimental MI.
2. Materials and methods
2.1. Genetically-modiﬁed mice and experimental MI
Transgenicmicewith cardiomyocyte or endothelium-targeted over-
expression of Nox2 (cardio-Nox2TG and endo-Nox2TG, respectively),
both on a C57BL/6 background, were described previously [15,16]. Per-
manent left coronary artery ligation or sham ligation was performed in
female TG mice and matched wild-type littermates (WT) aged 12–
18 weeks [9]. All procedures were performed in accordance with the
‘Guidance on the Operation of the Animals’ (Scientiﬁc Procedures) Act,
1986 (UK Home Ofﬁce) and institutional guidelines.
2.2. Infarct size
Cine-MRI with late Gadolinium enhancement (LGE) was performed
2 days after MI on a 7 T horizontal MR scanner (Varian, Palo Alto, CA)
[18]. MRI was repeated at day 28 post-MI (without LGE). The initial in-
farct area was estimated from the day 2 LGE images using a semi-auto-
mated in-house developed segmentation software (King's College
London, www.clinicalvolumes.com) [19]. Infarct area was expressed
as a percentage of total LV area and only animals with an infarct area
N30% were included in the study. Infarct size at 4 week follow-up was
estimated using infarct arc lengths rather than areas to avoid underesti-
mation relating to infarct thinning and compensatory non-infarct hy-
pertrophy, as previously described [20]. LV volumes and ejection
fraction (EF) were derived as described previously [19].
2.3. Echocardiography and in vivo LV hemodynamics
Echocardiography was performed under 2% isoﬂurane anesthesia at
heart rates N400 bpm, using a Vevo 2100 system with a 40 MHz linear
probe (Visualsonics, Canada) [16]. LV end diastolic volume (LVEDV),
LV end systolic volume (LVESV) and EF were measured using the
parasternal long axis view. Peak longitudinal strain of basal LV segments
was analyzed by high-frequency speckle tracking [21].
In vivo LV hemodynamics were determined by closed-chest pres-
sure-volume (PV) analysis using a 1.2F microconductance catheter sys-
tem (Scisense Inc., London, Ontario, Canada) introduced retrogradely
into the LV via the right carotid artery under 2% isoﬂurane anesthesia
(body temperature 37 °C). After stabilization, data were acquired via
an ADVantage™ system (Scisense Inc., London, Ontario, Canada)
coupled to a Powerlab/8SP with Chart Software (ADinstruments, UK).
Analysis was conducted using Labscribe, IWork Systems Inc., Dover,
NH [17].
2.4. Real-time RT-PCR
Total RNA was puriﬁed from non-infarct LV tissue using an SV RNA
extraction kit (Promega, UK). Expression of atrial natriuretic factor
(ANF), brain natriuretic peptide (BNP), beta-myosin heavy chain (β-
MHC),α-myosin heavy chain (α-MHC), connective tissue growth factor
(CTGF), ﬁbronectin, matrix metallopeptidase 2 (MMP2), and tissue
inhibitor of metalloproteinase 2 (TIMP2) mRNA was analyzed by real-
time RT-PCR using SYBR Green on an Applied Biosystem PRISM 7700
machine, with β-actin as an internal control. Standard curves were con-
structed from cDNA standards for each gene, and results were normal-
ized by expression as a molar/molar ratio to β-actin. The primers used
were (5′-3′): β-actin forward CGTGAAAAGATGACCCAGATCA, reverse
TGGTACGACCAGAGGCATACAG; ANF forward
CGTGCCCCGACCCACGCCAGCATGGGCTCC, reverse
GGCTCCGAGGGCCAGCGAGCAGAGCCCTCA; BNP forward
AAGGGAGAATACGGCATCATTG, reverse ACAGCACCTTCAGGAGATCCA;
β-MHC forward AGCAGCAGTTGGATGAGCGACT, reverse
CCAGCTCCTCGATGCGTGCC; α-MHC forward
TAAAATTGAGGACGAGCAGGC, reverse TCCAGCTCCTCGATGCGT; CTGF
forward GCTGCCTACCGACTGGAAGAC, reverse
GAACAGGCGCTCCACTCTG; ﬁbronectin forward
CCGGTGGCTGTCAGTCAGA, reverse CCGTTCCCACTGCTGATTTATC;
MMP2 forward TCGCCCATCATCAAGTTCCC, reverse
CCTTGGGGCAGCCATAGAAA and TIMP2 forward
GGTACCAGATGGGCTGTGA, reverse CATCCAGAGGCACTCATCCG.
2.5. Histology
Non-infarcted basal LV segments from hearts arrested in diastole
were ﬁxed in 1% paraformaldehyde and embedded on parafﬁn blocks
and onto slides. Cardiomyocyte cross-sectional area was measured
from sections stained with FITC-conjugated wheat germ agglutinin
(WGA, Vector RL-1022) [22]. Interstitial ﬁbrosis was assessed by
blinded quantitative image analysis of Picrosirius red-stained sections
[16]. Collagen content was quantiﬁed as the percentage of total LV
area under polarized light. Apoptosis was determined by terminal
deoxynucleotidyl transferase–mediated dUTP nick end-labelling
(TUNEL) staining according to the manufacturer's instructions (Roche
Applied Science). The number of apoptotic myocytes was counted,
and data were normalized per 105 total nuclei identiﬁed by DAPI stain-
ing in the same sections [9].
2.6. ROS levels
Superoxide levels in heart tissue were quantiﬁed using high-perfor-
mance liquid chromatography (HPLC)-based detection of
dihydroethidium (DHE) oxidation products [23]. Brieﬂy, hearts harvest-
ed from mice were cut into small pieces, weighed and immediately in-
cubated with DHE (100 μM in PBS) at 37 °C for 30 min. The sample
was then washed once with PBS. DHE and its oxidation products were
extracted with acetonitrile (500 μl), sonicated (3 × 30 s, 8 W), centri-
fuged (14,000 rpm, 10 min at 4 °C) and the supernatant dried under
vacuum. The samples were further dissolved in 120 μl PBS-DTPA and
injected into the HPLC system. The speciﬁc superoxide oxidation prod-
uct, 2-hydroxyethidine (EOH), was quantiﬁed by comparison of peak
signal between the samples and standard solutions under identical
chromatographic conditions. Results are expressed as the ratio of EOH
generated perDHE consumed (initial DHE concentrationminus remain-
ing DHE; EOH/DHE).
As a secondmethod, we quantiﬁed tyrosine nitrosylated proteins as
an index of nitroso-oxidativemodiﬁcation, by immunoblotting using an
anti-nitrotyrosine antibody (Abcam; 1:3000). Levels were normalized
by the level of actin in the same samples.
2.7. Statistics
Data are expressed as mean ± SEM of at least 3 independent exper-
iments. KaplanMeier survival curves were compared using the log rank
test. Other data were analyzed by unpaired Student t-test, 1-way or 2-
way ANOVA as appropriate, followed by Tukey post hoc analysis.
p b 0.05 was considered signiﬁcant.
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3. Results
3.1. Infarct size and survival
Infarct areameasured 48 h afterMI byMRI LGEwas not different be-
tween groups (Fig. 1A). Infarct size evaluated by MRI correlated well
with that by triphenyltetrazolium chloride (TTC) staining (data not
shown). Infarct area assessed at 4 weeks post-MI (as the thinned
akinetic area on MRI) was also similar in endo-Nox2TG and cardio-
Nox2TG as compared to their respective WT littermates (Fig. 1A). The
infarct areas both at early and late time points were comparable to
our previous studies [9]. Fig. 1B shows Kaplan Meier curves over a
4 week period and indicates that mortality rate was slightly although
non-signiﬁcantly higher in cardio-Nox2TGmice thanWT, while survival
rates in endo-Nox2TG were identical to those in WT mice.
3.2. LV dilatation and dysfunction
LV end-diastolic volume (LVEDV) assessed by echocardiography in-
creased signiﬁcantly over the 4weeks period afterMI, but therewere no
difference between the two TGgroups and respectiveWT animals in the
extent of LV dilatation (Fig. 2A and E). LVEF also decreased to a similar
extent in both TG groups and WT controls (Fig. 2B and F). Heart rates
were similar among groups (Fig. 2C and G). Similar results were
obtained by MRI (data not shown). To look for more subtle changes in
LV contractile function, we used high frequency speckle tracking analy-
sis [21]. The peak systolic longitudinal strain of LV basal non-infarcted
segments was signiﬁcantly reduced in mice 4 weeks post-MI, but
there were no differences between the cardio-Nox2TG or endo-
Nox2TG and their respective WT controls (Fig. 2D and H).
3.3. LV hemodynamics
We assessed contractile function by in vivo cardiac catheterization.
Both LVdP/dtmax and LV dP/dtmax/LVEDV -measures of systolic function
- were decreased 4 weeks after MI but to a similar extent in all groups
(Fig. 3A, B, E and F). LV dP/dtmin and the isovolumic relaxation time con-
stant, τ, as measures of diastolic function were also impaired after MI
but again there was no signiﬁcant difference between TG and WT (Fig.
3C, D, G and H).
3.4. ROS levels, cardiomyocyte hypertrophy, ﬁbrosis and apoptosis
Myocardial superoxide levels assessed by HPLC of DHE oxidation
products increased after MI both in cardio-Nox2TG mice and their WT
littermates but the increase was signiﬁcantly greater in the former
group (Fig. 4A). In line with this, the protein levels of nitrotyrosine
were signiﬁcantly higher in cardio-Nox2TG mice than WT after MI
Fig. 1. Infarct size and survival rate post-MI. A. Infarct size assessed byMRI at 2 days and 4weeks post-MI. RepresentativeMRI images are shown below; arrows indicate infarct area by LGE
at 2 days and area of infarct scar at 4 weeks post-MI. B. Kaplan Meier survival curves for endo-Nox2TG, cardio-Nox2TG and respective WT controls after MI.
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(Fig. 4B). The cardiomyocyte cross-sectional area in the remotemyocar-
dium increased after MI, and the increase was signiﬁcantly higher in
cardio-Nox2TG mice than WT (Fig. 4C, Supplementary Fig. 1A). ANF
mRNA expression levels, as a molecular marker of hypertrophy, also
tended to increasemore in cardio-Nox2TG thanWT (Fig. 4D). Other hy-
pertrophic markers, namely BNP and β-MHC increased after MI while
α-MHC decreased, but the responses were similar in cardio-Nox2TG
mice andWT littermates (Supplementary Fig. 1B–D). Interstitial ﬁbrosis
increased afterMI,with a signiﬁcantly higher increase in cardio-Nox2TG
mice compared toWT (Fig. 4E, Supplementary Fig.1E). ThemRNA levels
of CTGF, ﬁbronectin and the matrix-regulating enzymes MMP2 and
TIMP2 were similar between groups (Supplementary Fig. 1F–I). The
level of cardiomyocyte apoptosis was similarly increased in cardio-
Nox2TG and WT hearts post-MI (Fig. 4F).
In the endo-Nox2TG group, the myocardial levels of superoxide and
protein levels of nitrotyrosine increased afterMI to a similar extent as in
WT littermates (Fig. 5A, B). We also found a similar increase in endo-
Nox2TG and WT groups in myocyte cross-sectional area (Fig. 5C, Sup-
plementary Fig. 2A) and ANF mRNA levels (Fig. 5D). Other molecular
markers of hypertrophy were no different between groups (Supple-
mentary Fig. 2B–D). The degree of interstitial ﬁbrosis and mRNA levels
of ﬁbrotic markers and matrix-regulating proteins were similar be-
tween endo-Nox2TG and WT after MI (Fig. 5E, F and Supplementary
Fig. 2E–H).
Fig. 2. LV volume and function after MI as assessed by echocardiography. LVEDV, left ventricle end diastolic volume; EF, ejection fraction; HR, heart rate. *p b 0.05 vs respective sham
controls. n= 5–9/group for endo-Nox2TG, n ≥ 7/group for cardio-Nox2TG.
Fig. 3. LV hemodynamics afterMI. LVdP/dtmax, LVdP/dtmax/LVEDV, LVdP/dtmin and isovolumic relaxation time constant tau are shown. *p b 0.05, **p b 0.01 vs respective sham controls.
n= 4–8/group.
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Thus, cardio-Nox2TG mice develop more remodeling (hypertrophy
and ﬁbrosis) of the non-infarct myocardium than do the endo-Nox2TG
mice or WT animals, effects which are accompanied by higher ROS
levels in the cardio-Nox2TG mice than WT.
4. Discussion
Increasing evidence indicates that enhancedROSproduction and ox-
idative stress are involved in post-MI remodeling, contributing to cell
Fig. 4. ROS production, cardiomyocyte cross-sectional area (CSA), interstitial ﬁbrosis and apoptosis afterMI in cardio-Nox2TGmice. (A) Levels of superoxide in the heart assessed by HPLC
analysis of DHE oxidation product EOH. (B) Protein levels of nitrotyrosine assessed byWestern blot. (C)Mean data for cardiomyocyte area and (E) interstitial ﬁbrosis. (D) Atrial natriuretic
factor (ANF) mRNA expression. (E) TUNEL-positive cells. *p b 0.05, **p b 0.01 vs respective sham controls. ## p b 0.01 vs WT/MI, n= 4–7/group.
Fig. 5. ROS production, cardiomyocyte cross-sectional area (CSA) and interstitial ﬁbrosis after MI in endo-Nox2TGmice. (A) Levels of superoxide in the heart assessed by HPLC analysis of
DHE oxidation product EOH. (B) Protein levels of nitrotyrosine assessed by Western blot. (C) Mean data for cardiomyocyte area and (E) interstitial ﬁbrosis. (D) Atrial natriuretic factor
(ANF) and (F) Connective tissue growth factor (CTGF) mRNA expression.*p b 0.05, **p b 0.01 vs respective sham controls. n= 4–7/group.
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death and inﬂammation in the early phases and to cardiomyocyte hy-
pertrophy, ﬁbrosis, LV chamber dilatation and contractile dysfunction
in the late phase afterMI [24]. Several ROS sourcesmay in principle con-
tribute to ROS production, for example mitochondria, uncoupled nitric
oxide synthases, xanthine oxidases and NADPH oxidases. Among these
sources, Nox2 is especially implicated in adverse LV remodeling based
on previous ﬁndings from several different types of study. The levels
of Nox2 increase 1.5–4 fold in the infarct region and the remotemyocar-
diumafterMI, both in experimentalmodels and in humans [10–14]. The
global deletion of Nox2 or its regulatory subunit p47phox was found to
reduce the extent of MI-induced adverse remodeling, heart failure and
rupture [9,10,25]. Furthermore, agents that inhibit Nox2oxidase activity
such as apocynin and statins have been found to have beneﬁcial effects
on adverse post-MI LV remodeling [26–28]. Local delivery of siRNA to si-
lence Nox2 could also improve cardiac function followingMI [29]. These
studies clearly indicate that an increase in Nox2 levels and activity after
MI contribute to detrimental LV remodeling. Since Nox2 is expressed
both in the endotheliumand in cardiomyocytes, and recent studies indi-
cate cell-speciﬁc effects [16,17,30], it is of interest to identify the impact
Nox2 in these cell types has during the response toMI. In this study, we
took advantage of two transgenicmodels recently developed in our lab-
oratory inwhich the levels of Nox2 aremodestly (2–5-fold) increased in
either the cardiomyocyte or the endothelium [15,16]. This level of in-
crease in Nox2 is in a pathophysiologically relevant range, being similar
to levels previously reported in the literature [10,13,14]. Importantly, it
was shown in thesemodels that levels of other oxidase complex compo-
nents were not affected by this modest level of increase in Nox2 nor
were there changes in antioxidant genes [15,16]. These models there-
fore allowed us to investigate the cell-speciﬁc effects of Nox2 during
post-MI LV remodeling.
We found that an increase in cardiomyocyte Nox2 levels resulted in
signiﬁcantly greater cardiomyocyte hypertrophy and interstitial ﬁbrosis
in the remotemyocardium after MI as compared toWT littermatemice,
indicating that cardiomyocyte Nox2 aggravates this aspect of the LV re-
modeling response. These effects were accompanied by evidence of sig-
niﬁcantly higher ROS levels in cardio-Nox2Tg myocardium than WT.
These results indicate that cardiomyocyteNox2 aggravates hypertrophy
and ﬁbrosis post-MI and are in line with previous studies that demon-
strated a Nox2-ROS-mediated enhancement of cultured cardiomyocyte
hypertrophy [31,32], and that Nox2 promotes cardiac ﬁbrosis [33]. The
mechanisms involved in the hypertrophic effects included a Nox2-me-
diated enhancement of ERK1/2 and Akt signaling in cardiomyocytes,
while mechanisms promoting ﬁbrosis included the production of con-
nective tissue growth factor (CTGF), NF-κB signaling and MMP activa-
tion [31–33]. We observed increases in ANF mRNA levels in cardio-
Nox2Tg mice compared to WT after MI but other molecular markers
of hypertrophy and genes potentially involved in ﬁbrosis were not dif-
ferent between groups. This may be because the extent of increase in
hypertrophy and ﬁbrosis was relativelymodest and changes in gene ex-
pression may have been transient. We also did not observe a difference
in LV dysfunction between cardio-Nox2 Tg mice and WT but the Tg
group tended to have a higher mortality after MI. Our transgenic mice
have quite modest increases in Nox2 activity [16] and it is likely that a
greater increase in Nox2 might result in detrimental effects also on LV
contractile function.
In contrast to the cardio-Nox2TG mice, we found that endo-Nox2TG
showed no differences from WT in any parameter after MI. While the
lack of effect on cardiomyocyte hypertrophy was expected (because
Nox2 was overexpressed in endothelial cells), our previous study in
these mice in a model of chronic angiotensin II stimulation showed
that endothelial Nox2 can enhance endothelial-mesenchymal transi-
tion, ﬁbrosis and diastolic dysfunction [17]. However, we found no evi-
dence in the present study of either enhanced ﬁbrosis or worse diastolic
dysfunction after MI in thesemice. In linewith this, althoughmyocardi-
al ROS levels rose after MI, there was no difference between the extent
of increase in endo-Nox2Tg mice and WT littermates. This ﬁnding
indicates that the effects of endothelial Nox2 may depend upon the
stress stimulus and there may be a differential activation of endothelial
versus cardiomyocyte Nox2 after MI.
Increasing data indicates that the effects of ROS depend not only
upon the enzymatic source but also the cell type(s) within which they
are generated. This is especially so for ROS effects that involve themod-
ulation of intracellular signaling pathways. The current results suggest
that cardiomyocyte rather than endothelial Nox2 has the greater impact
on adverse remodeling after MI. These results add to the evidence that
the pathophysiological effects of Noxs are isoform-speciﬁc, cell-speciﬁc
and context-speciﬁc. This complexity will be important to bear in mind
in developing therapeutic approaches that target the detrimental effects
of Noxs in the heart.
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